Currentsierra health and lifePolicy 2026T0630J

Sacral Nerve Stimulation for Urinary and Fecal Indications – Commercial and Individual Exchange Medical Policy

Medical policy for sacral nerve stimulation (SNS/SNM) applied to UnitedHealthcare Commercial and Individual Exchange plans for individuals age ≥18, defining medical necessity criteria for screening trial, permanent implantation, revisions/replacements, and exclusion/unproven indications (constipation, chronic pelvic pain). Covers urinary voiding dysfunction and fecal incontinence.

Policy Summary

Payersierra health and life

PolicySacral Nerve Stimulation for Urinary and Fecal Indications – Commercial and Individual Exchange Medical Policy

Policy CodePolicy 2026T0630J

Change TypeRevised reference link (02/01/2026)

Effective DateJan 1, 2026

Next Review Date

Key ActionDocument that symptoms are refractory to conservative care and that the individual achieved a successful screening trial (>=50% improvement) before offering permanent implantation.

SourceLink

POLICY UPDATE CHANGES

02/01/2026 - Updated reference link to reflect the current policy title for Gastrointestinal Disorders Diagnostic Procedures.

Age >=18Applicable population

>=50%Screening trial improvement required

>=100 mLMinimum bladder capacity

Unproven

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

SNS for Constipation and CPP

35%Aggregate revision rate (FI review)

7 daysTypical PNE bladder test duration

Coverage Summary

Scope: This UnitedHealthcare policy (Policy Number 2026T0630J, effective January 1, 2026) applies to Commercial and Individual Exchange plans and addresses sacral nerve stimulation/sacral neuromodulation (SNS/SNM) for urinary voiding dysfunction and fecal incontinence in individuals aged ≥ 18 years. High-level coverage thresholds: candidates must be adults (≥18), have indications limited to urinary voiding dysfunction or fecal incontinence (not constipation or chronic pelvic pain, which are considered unproven), and must complete a documented SNS screening trial. Permanent implantation is covered only when the screening trial demonstrates documented symptom improvement of ≥ 50%.

Key thresholds and quick facts

Applicable populationAge >=18

Required screening trial improvement for permanent implant>= 50% improvement

Minimum bladder capacity for urinary screening trial>= 100 mL

Typical PNE (test) duration - bladder~7 days

Typical PNE (test) duration - bowel10-21 days

Typical Stage 1 test duration2-3 weeks

Chronic urinary retention definitionPVR >= 300 mL persisting >= 6 months (documented on >=2 occasions)

Medical Necessity Criteria

Guidance, Test-phase & Success Criteria

Coding

Relevant CPT / HCPCS Procedure Codes (listed for reference)CPT|HCPCS|mixed

0784T	Insertion or replacement of percutaneous electrode array, spinal, with integrated neurostimulator, including imaging guidance, when performed.
0785T	Revision or removal of neurostimulator electrode array, spinal, with integrated neurostimulator.
0786T	Insertion or replacement of percutaneous electrode array, sacral, with integrated neurostimulator, including imaging guidance, when performed.
0787T	Revision or removal of neurostimulator electrode array, sacral, with integrated neurostimulator.
64561	Percutaneous implantation of neurostimulator electrode array; sacral nerve (transforaminal placement) including image guidance, if performed.
64581	Open implantation of neurostimulator electrode array; sacral nerve (transforaminal placement).
64585	Revision or removal of peripheral neurostimulator electrode array.
64590	Insertion or replacement of peripheral, sacral, or gastric neurostimulator pulse generator or receiver, requiring pocket creation and connection between electrode array and pulse generator or receiver.
64595	Revision or removal of peripheral, sacral, or gastric neurostimulator pulse generator or receiver, with detachable connection to electrode array.
L8679	Implantable neurostimulator, pulse generator, any type.

1–10 of 16

1/2

Urinary Diagnosis Codes (listed for reference)ICD-10

N32.81	Overactive bladder.
N32.9	Bladder disorder, unspecified.
N39.3	Stress incontinence (female) (male).
N39.41	Urge incontinence.
N39.42	Incontinence without sensory awareness.
N39.46	Mixed incontinence
N39.490	Overflow incontinence.
N39.498	Other specified urinary incontinence.
R30.0	Dysuria.
R30.1	Vesical tenesmus.

1–10 of 31

1/4

Fecal Indications Diagnosis Codes (listed for reference)ICD-10

R15.0	Incomplete defecation.
R15.1	Fecal smearing.
R15.2	Fecal urgency.
R15.9	Full incontinence of feces

Regulatory device approvals (informational)mixed

P970004	Medtronic InterStim PMA for urinary control (original InterStim)
S004	Medtronic supplement approval for urinary retention
S302	Medtronic InterStim Micro device approval (2020)
P190006	Axonics r-SNM System PMA for chronic fecal incontinence (2019)
P240031	Neuspera Sacral Neuromodulation System PMA for UUI (noted as approved June 18, 2025 in text)

Provider Actions & Billing Requirements

Prior Authorization

Requirement for screening trial success prior to permanent implant

A percutaneous or staged screening trial demonstrating adequate symptomatic improvement is required prior to approval for permanent sacral nerve stimulator implantation for urinary or fecal indications. The screening trial must document patient selection, trial-phase response, and that the individual is capable of operating the device. Trial success is defined as improvement in reported symptoms of 50% or greater compared to baseline. For neurogenic patients, screening and selection must include documentation that symptoms are not attributable to a progressive neurologic disease (for example, Parkinson's disease, stroke, spinal cord injury, or multiple sclerosis) unless there is clear evidence supporting benefit in that specific neurogenic condition. Preoperative counseling and informed consent must be documented, including discussion of expected benefits, risks (including need for revision or removal), alternative therapies, and device operation requirements.

Screening trial required and must show ≥50% symptom improvement to qualify for permanent implant.
Document rationale for selecting neurogenic patients; exclude cases where dysfunction is clearly secondary to progressive neurologic disease unless justifying evidence is provided.
Confirm and document that individual is capable of operating the sacral nerve stimulating device.
Preoperative counseling and informed consent must be present in the medical record.

Background & Evidence Summary

Background: Sacral nerve stimulation/sacral neuromodulation (SNS/SNM) is a minimally invasive neuromodulation therapy for overactive bladder, urge incontinence, nonobstructive urinary retention, and fecal incontinence. Typical test-phase approach: individuals usually undergo a 3–7 day percutaneous nerve evaluation (PNE) trial for bladder indications (with bowel PNE often lasting 10–21 days), or a Stage 1 lead test lasting typically 2–3 weeks when longer evaluation is needed. Permanent implantation follows when the screening/test trial meets the success threshold of ≥ 50% symptom improvement.

Evidence summary metrics

Pooled test stimulation success rate (meta-analysis)~66.2% (pooled test success rate reported)

Pooled permanent SNM success rate (meta-analysis)~84.2% (pooled permanent success rate reported)

Eggers et al. 2025 (FI systematic review) - long-term per-protocol success range59.4%–87.5% (per-protocol analyses); ITT 20.9%–87.5%

Eggers et al. 2025 - device adverse summariesAggregate revision rate 35.2%; explant rate 19.7%; improvements in bowel diaries and QoL at >=36 months but serious risk of bias/heterogeneity

Definitions

Term	Definition
Chronic Urinary Retention	PVR >= 300 mL that persists for >= 6 months and is documented on >= 2 separate occasions.
Fecal Incontinence (FI)	Involuntary passage of fecal matter through the anus or inability to control discharge of bowel contents.
Chronic Pelvic Pain (CPP)	Persistent or recurrent episodic pelvic pain with associated lower urinary tract, sexual, bowel, or gynecological dysfunction without proven infection or other obvious pathology.
PNE	Percutaneous nerve evaluation - temporary test stimulation prior to permanent implantation.
Stage 1 test	Surgical placement of a test lead for a longer trial period, typically 2-3 weeks, used when PNE is questionable or longer testing is required.
FI	Fecal incontinence.
OAB/UUI	Overactive bladder / Urgency urinary incontinence.
LARS	Low Anterior Resection Syndrome.
STC	Slow transit constipation.
PNE	Percutaneous nerve evaluation (test stimulation) period.
Stage 1 testing	Operative percutaneous or lead-based temporary test stimulation prior to permanent implant.

Revision History

02/01/2026revisedLatest

Updated reference link to reflect the current policy title for Gastrointestinal Disorders Diagnostic Procedures.

01/01/2026revised

Template update created shared policy version to support application to Oxford plan membership; archived previous policy version 2025T0630I and SURGERY 125.5.

Policy Summary

Payersierra health and life

PolicySacral Nerve Stimulation for Urinary and Fecal Indications – Commercial and Individual Exchange Medical Policy

Policy CodePolicy 2026T0630J

Change TypeRevised reference link (02/01/2026)

Effective DateJan 1, 2026

Next Review Date

Key ActionDocument that symptoms are refractory to conservative care and that the individual achieved a successful screening trial (>=50% improvement) before offering permanent implantation.

SourceLink

On This Page

Documentation Required

Document conservative therapy failure

Document prior conservative therapy attempts and failure before proceeding with a screening trial or permanent implantation. Conservativetherapy may include bladder/bowel training, pelvic floor rehabilitation, behavioral interventions, pharmacologic therapy, bulking agents (for fecal incontinence), and other noninvasive measures.

Specify therapies tried, durations, and reasons for inadequate response.

Documentation Required

Document device operation capability

Document that the individual can operate and manage the implanted sacral nerve stimulation device, including ability to use external programmers or recharge systems if applicable.

Assessment of cognitive and manual dexterity to manage device functions.
Caregiver availability if patient cannot self-manage.

Documentation Required

Exclude secondary causes

Exclude secondary causes of urinary or fecal dysfunction prior to implantation. Document evaluation and exclusion of mechanical obstruction, distorted anorectal anatomy, constipation-related causes, active infection, and progressive neurologic disease when applicable.

Examples: prostate obstruction, urethral stricture, anorectal malformation, abscess/fistula, recent rectal surgery, or active pelvic malignancy.

Documentation Required

Document trial-phase improvement

Document the magnitude of symptom improvement during the screening (trial) phase. The medical record must include baseline and trial-period symptom measures (for example voiding diaries, frequency/urgency episodes, incontinence episodes, or validated scoring tools) demonstrating ≥50% improvement.

Include objective measures where available (voiding diary entries, stool/continence counts).
Record duration of trial and stimulation parameters used.

Documentation Required

Preoperative counseling documentation

Document that preoperative counseling and informed consent were obtained and documented in the record, covering: expected benefits, potential risks and complications (including need for revision/removal), alternative treatments, device management requirements, and the criteria for proceeding from trial to permanent implantation.

Signed informed consent form or detailed progress note describing the counseling discussion.
Documentation that patient understands device care and follow-up requirements.

Documentation Required

Screening and selection for neurogenic patients

For patients with neurologic disease or neurogenic lower urinary tract dysfunction, document screening and selection considerations: clearly state the neurologic diagnosis, stability/progression of the neurologic disease, prior treatments, and the rationale for trialing sacral nerve stimulation. Provide evidence supporting anticipated benefit in the neurogenic condition and document specialist consultation when appropriate.

Document that the dysfunction is not clearly secondary to a progressive neurologic disorder unless supported by evidence.
Include consultation notes (e.g., neurology, urology, colorectal) when neurogenic pathology is present.

Documentation Required

Document test stimulation outcomes

Document the outcomes of test stimulation sessions, including technical details and clinical response. Records should include stimulation parameters, lead placement details, any intra-procedural testing results, and adverse events during the trial.

Include imaging or operative reports describing lead position when available.
Record any complications or reasons for trial termination.

Billing Rule

Use listed CPT/HCPCS/ICD-10 codes for claims

Use listed CPT, HCPCS, and ICD-10 codes for claims submission. The following codes are provided for reference; listing does not guarantee coverage and documentation must support medical necessity.

CPT: 0784T, 0785T, 0786T, 0787T, 64561, 64581, 64585, 64590, 64595
HCPCS: L8679, L8680, L8682, L8685, L8686, L8687, L8688
ICD-10 (examples): N32.81, N32.9, N39.3, N39.41, N39.42, N39.46, N39.490, N39.498, R30.0, R30.1, R30.9, R32, R33.0, R33.8, R33.9, R35.0, R35.1, R35.81, R35.89, R39.11, R39.12, R39.13, R39.14, R39.15, R39.16, R39.191, R39.192, R39.198, R39.81, R39.89, R39.9, R15.0, R15.1, R15.2, R15.9

Major systematic review / meta-analysis highlightsvan Ophoven et al. pooled test success 66.2% and pooled permanent success 84.2%; limits include heterogeneity and risk of bias

Placebo / sham findings relevant to FI/constipation trialsSham stimulation associated with meaningful symptom improvements indicating notable placebo effects